Abstract
Sphingosine kinase 1 (SPHK1) is overexpressed in solid tumors and leukemia. However, the mechanism of SPHK1 overexpression by oncogenes has not been defined. We found that v-Src-transformed NIH3T3 cells showed a high SPHK1 mRNA, SPHK1 protein and SPHK enzyme activity. siRNA of SPHK1 inhibited the growth of v-Src-NIH3T3, suggesting the involvement of SPHK1 in v-Src-induced oncogenesis. v-Src-NIH3T3 showed activations of protein kinase C-α, signal transducers and activators of transcription 3 and c-Jun NH2-terminal kinase. Their inhibition suppressed SPHK1 expression in v-Src-NIH3T3, whereas their overexpression increased SPHK1 mRNA in NIH3T3. Unexpectedly, the nuclear run-on assay and the promoter analysis using 5′-promoter region of mouse SPHK1 did not show any significant difference between mock- and v-Src-NIH3T3. Furthermore, the half-life of SPHK1 mRNA in mock-NIH3T3 was nearly 15 min, whereas that of v-Src-NIH3T3 was much longer. Examination of two AU-rich region-binding proteins, AUF1 and HuR, that regulate mRNA decay reciprocally, showed decreased total AUF1 protein associated with increased tyrosine-phosphorylated form and increased serine-phosphorylated HuR protein in v-Src-NIH3T3. Modulation of AUF1 and HuR by their overexpression or siRNA revealed that SPHK1 mRNA in v-Src- and mock-NIH3T3 was regulated reciprocally by these factors. Our results showed, for the first time, a novel mechanism of v-Src-induced SPHK1 overexpression.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akao Y, Banno Y, Nakagawa Y, Hasegawa N, Kim TJ, Murate T et al. (2006). High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation. Biochem Biophys Res Commun 342: 1284–1290.
Alvarez SE, Milstien S, Spiegel S . (2007). Autocrine and paracrine roles of sphingosine-1-phosphate. Trends Endocrinol Metab 18: 300–307.
Bektas M, Jolly PS, Müller C, Eberle J, Spiegel S, Geilen CC . (2005). Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene 24: 178–187.
Blobel GA, Hanafusa H . (1991). The v-src inducible gene 9E3/pCEF4 is regulated by both its promoter upstream sequence and its 3′ untranslated region. Proc Natl Acad Sci USA 88: 1162–1166.
Bonhoure E, Pchejetski D, Aouali N, Morjani H, Levade T, Kohama T et al. (2006). Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia 20: 95–102.
Borner C, Guadagno SN, Hsiao WW, Fabbro D, Barr M, Weinstein IB . (1992). Expression of four protein kinase C isoforms in rat fibroblasts. Differential alterations in ras-, src-, and fos-transformed cells. J Biol Chem 267: 12900–12910.
Bromann PA, Korkaya H, Webb CP, Miller J, Calvin TL, Courtneidge SA . (2005). Platelet-derived growth factor stimulates Src-dependent mRNA stabilization of specific early genes in fibroblasts. J Biol Chem 280: 10253–10263.
Chen CY, Del Gatto-Konczak F, Wu Z, Karin M . (1998). Stabilization of interleukin-2 mRNA by the c-Jun NH2-terminal kinase pathway. Science 280: 1945–1949.
Chen CY, Gherzi R, Ong SE, Chan EL, Raijmakers R, Pruijn GJ et al. (2001). AU binding proteins recruit the exosome to degrade ARE-containing mRNAs. Cell 107: 451–464.
Cussac D, Greenland C, Roche S, Bai RY, Duyster J, Morris SW et al. (2004). Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood 103: 1464–1471.
Dehm S, Senger MA, Bonham K . (2001). SRC transcriptional activation in a subset of human colon cancer cell lines. FEBS Lett 487: 367–371.
Dehm SM, Bonham K . (2004). SRC gene expression in human cancer: the role of transcriptional activation. Biochem Cell Biol 82: 263–274.
Doller A, Huwiler A, Muller R, Radeke HH, Pfeilschifter J, Eberhardt W . (2007). Protein kinase C alpha-dependent phosphorylation of the mRNA-stabilizing factor HuR: implications for posttranscriptional regulation of cyclooxygenase-2. Mol Biol Cell 18: 2137–2148.
Fawal M, Armstrong F, Ollier S, Dupont H, Touriol C, Monsarrat B et al. (2006). A ‘liaison dangereuse’ between AUF1/hnRNPD and the oncogenic tyrosine kinase NPM-ALK. Blood 108: 2780–2788.
Frame MC . (2004). Newest findings on the oldest oncogene; how activated src does it. J Cell Sci 117: 989–998.
French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL et al. (2003). Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 63: 5962–5969.
Fritz G, Kaina B, Aktories K . (1995). The ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments. J Biol Chem 270: 25172–25177.
Gartsbein M, Alt A, Hashimoto K, Nakajima K, Kuroki T, Tennenbaum T . (2006). The role of protein kinase C delta activation and STAT3 Ser727 phosphorylation in insulin-induced keratinocyte proliferation. J Cell Sci 119: 470–481.
Good PJ . (1992). A conserved family of elav-like genes in vertebrates. Proc Natl Acad Sci USA 92: 4557–4561.
Greulich H, Reichman C, Hanafusa H . (1996). Delay in serum stimulation of Erk activity caused by oncogenic transformation. Oncogene 12: 1689–1695.
Hanford DS, Glembotski CC . (1996). Stabilization of the B-type natriuretic peptide mRNA in cardiac myocytes by alpha-adrenergic receptor activation: potential roles for protein kinase C and mitogen-activated protein kinase. Mol Endocrinol 10: 1719–1727.
Karni R, Dor Y, Keshet E, Meyuhas O, Levitzki A . (2002). Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1 alpha expression under normoxia. J Biol Chem 277: 42919–42925.
Kawamori T, Osta W, Johnson KR, Pettus BJ, Bielawski J, Tanaka T et al. (2006). Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J 20: 386–388.
Kloss S, Srivastava R, Mulsch A . (2004). Down-regulation of soluble guanylyl cyclase expression by cyclic AMP is mediated by mRNA-stabilizing protein HuR. Mol Pharmacol 65: 1440–1451.
Kuo L, Chang HC, Leu TH, Maa MC, Hung WC . (2006). Src oncogene activates MMP-2 expression via the ERK/Sp1 pathway. J Cell Physiol 207: 729–734.
Lal A, Mazan-Mamczarz K, Kawai T, Yang X, Martindale JL, Gorospe M . (2004). Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs. EMBO J 23: 3092–3102.
Leclerc GJ, Leclerc GM, Barredo JC . (2002). Real-time RT–PCR analysis of mRNA decay: half-life of beta-actin mRNA in human leukemia CCRF-CEM and Nalm-6 cell lines. Cancer Cell Int 2: 1–5.
Liu H, Sugiura M, Nava VE, Edsall LC, Kono K, Poulton S et al. (2000). Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem 275: 19513–19520.
Lopez de Silanes I, Zhan M, Lal A, Yang X, Gorospe M . (2004). Identification of a target RNA motif for RNA-binding protein HuR. Proc Natl Acad Sci USA 101: 2987–2992.
Meyer S, Temme C, Wahle E . (2004). Messenger RNA turnover in eukaryotes: pathways and enzymes. Crit Rev Biochem Mol Biol 39: 197–216.
Murakami M, Ichihara M, Sobue S, Kikuchi R, Ito H, Kimura A et al. (2007). RET signaling-induced SPHK1 gene expression plays a role in both GDNF-induced differentiation and MEN2-type oncogenesis. J Neurochem 102: 1585–1594.
Nakade Y, Banno Y, T-Koizumi K, Hagiwara K, Sobue S, Koda M et al. (2003). Regulation of sphingosine kinase 1 gene expression by protein kinase C in a human leukemia cell line, MEG-O1. Biochim Biophys Acta 1635: 104–116.
Olivera A, Kohama T, Edsall L, Nava V, Cuvillier O, Poulton S et al. (1999). Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J Cell Biol 14: 545–558.
Pan YX, Chen H, Kilberg MS . (2005). Interaction of RNA-binding proteins HuR and AUF1 with the human ATF3 mRNA 3′-untranslated region regulates its amino acid limitation-induced stabilization. J Biol Chem 280: 34609–34616.
Park YJ, Park ES, Kim MS, Kim TY, Lee HS, Lee S et al. (2002). Involvement of the protein kinase C pathway in thyrotropin-induced STAT3 activation in FRTL-5 thyroid cells. Mol Cell Endocrinol 194: 77–84.
Patrone G, Puppo F, Cusano R, Scaranari M, Ceccherini I, Puliti A et al. (2000). Nuclear run-on assay using biotin labeling, magnetic bead capture and analysis by fluorescence-based RT–PCR. Biotechniques 29: 1012–1014, 1016–1017.
Qureshi SA, Cao XM, Sukhatme VP, Foster DA . (1991). v-Src activates mitogen-responsive transcription factor Egr-1 via serum response elements. J Biol Chem 266: 10802–10806.
Raineri I, Wegmueller D, Gross B, Certa U, Moroni C . (2004). Roles of AUF1 isoforms, HuR and BRF1 in ARE-dependent mRNA turnover studied by RNA interference. Nucleic Acids Res 32: 1279–1288.
Shih SC, Mullen A, Abrams K, Mukhopadhyay D, Claffey KP . (1999). Role of protein kinase C isoforms in phorbol ester-induced vascular endothelial growth factor expression in human glioblastoma cells. J Biol Chem 274: 15407–15414.
Sobue S, Hagiwara K, Banno Y, Tamiya-Koizumi K, Suzuki M, Takagi A et al. (2005). Transcription factor specificity protein 1 (Sp1) is the main regulator of nerve growth factor-induced sphingosine kinase 1 gene expression of the rat pheochromocytoma cell line, PC12. J Neurochem 95: 940–949.
Sobue S, Iwasaki T, Sugisaki C, Nagata K, Kikuchi R, Murakami M et al. (2006). Quantitative RT–PCR analysis of sphingolipid metabolic enzymes in acute leukemia and myelodysplastic syndromes. Leukemia 20: 2042–2046.
Stoeckle MY, Hanafusa H . (1989). Processing of 9E3 mRNA and regulation of its stability in normal and Rous sarcoma virus-transformed cells. Mol Cell Biol 9: 4738–4745.
Stofega MR, Yu CL, Wu J, Jove R . (1997). Activation of extracellular signal-regulated kinase (ERK) by mitogenic stimuli is repressed in v-Src-transformed cells. Cell Growth Differ 8: 113–119.
Taha TA, Hannun YA, Obeid LM . (2006). Sphingosine kinase: biochemical and cellular regulation and role in disease. J Biochem Mol Biol 39: 113–131.
Tezuka K, Denhardt DT, Rodan GA, Harada S . (1996). Stimulation of mouse osteopontin promoter by v-Src is mediated by a CCAAT box-binding factor. J Biol Chem 271: 22713–22717.
Turkson J, Bowman T, Adnane J, Zhang Y, Djeu JY, Sekharam M et al. (1999). Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol Cell Biol 19: 7519–7528.
Vlasova IA, McNabb J, Raghavan A, Reilly C, Williams DA, Bohjanen KA et al. (2005). Coordinate stabilization of growth-regulatory transcripts in T cell malignancies. Genomics 86: 159–171.
Wilson GM, Lu J, Sutphen K, Sun Y, Huynh Y, Brewer G . (2003). Regulation of A + U-rich element-directed mRNA turnover involving reversible phosphorylation of AUF1. J Biol Chem 278: 33029–33038.
Wilusz CJ, Wormington M, Peltz SW . (2001). The cap-to-tail guide to mRNA turnover. Nat Rev Mol Cell Biol 2: 237–246.
**a P, Gamble JR, Wang L, Pitson SM, Moretti PA, Wattenberg BW et al. (2000). An oncogenic role of sphingosine kinase. Curr Biol 10: 1527–1530.
**e W, Herschman HR . (1995). v-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor. J Biol Chem 270: 27622–27628.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
Supplementary information
Rights and permissions
About this article
Cite this article
Sobue, S., Murakami, M., Banno, Y. et al. v-Src oncogene product increases sphingosine kinase 1 expression through mRNA stabilization: alteration of AU-rich element-binding proteins. Oncogene 27, 6023–6033 (2008). https://doi.org/10.1038/onc.2008.198
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2008.198
- Springer Nature Limited